spot_img
12 C
London
HomeInvestors HealthAutolus wins FDA approval of Aucatzyl for acute lymphoblastic leukemia

Autolus wins FDA approval of Aucatzyl for acute lymphoblastic leukemia


T-Cell Targeting Cancer Cells

luismmolina/iStock via Getty Images

The U.S. FDA has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Approval was based on results from the FELIX study, an open-label, multicenter, single-arm trial



Source link

latest articles

explore more

LEAVE A REPLY

Please enter your comment!
Please enter your name here